Cosciens Biopharma Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Cosciens Biopharma Inc (CSCI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Cosciens Biopharma Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 7M vs 702M combined for tracked competitors (1.1% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-5.8% annualized vs trailing 12 months), vs decelerating (-32.5%) for its tracked peer group.
- Growth: Cosciens Biopharma Inc generated -46.8% revenue growth year over year in Q4 2025, vs -11.1% for its tracked competitors combined.
- Profitability: Its -123.6% net margin compares with -8.5% for the peer group.
- Peer revenue share: Cosciens Biopharma Inc accounted for 1.5% of combined revenue among its tracked peer group, down from 2.4% a year earlier.
- Peer differentiation: Revenue per employee of $0.27M compares with $0.78M for the peer group (0.3x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CSCI Sales vs. its Competitors, Q4 2025
Cosciens Biopharma Inc reported revenue contraction of 46.84 % year on year in Q4 2025, below its competitors' combined revenue change of -11.07 %.
With a net margin of -123.61 %, Cosciens Biopharma Inc reported lower profitability than its competitors (-8.48 %).
Cosciens Biopharma Inc generated 1.47 % of the combined sales of its peer group, down from 2.44 % a year earlier.
Cosciens Biopharma Inc vs. its Competitors, Q4 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Cosciens Biopharma Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Cosciens Biopharma Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (2) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Cosciens Biopharma Inc's competitor groups requires a Commercial License.
For context: the Personal & Household Products industry grew revenue 0.1% year over year, combined, vs -46.8% for Cosciens Biopharma Inc. Cosciens Biopharma Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Cosciens Biopharma Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Cosciens Biopharma Inc | - | No | No | No |
| Competitors combined (13) | ||||
| High-Confidence Competitors (2) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CSCI Stock Performance relative to its Competitors
CSCI Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ironwood Pharmaceuticals inc | 282.9% | Outperformed |
| 2 | Relmada Therapeutics Inc | 282.9% | Outperformed |
| 3 | Talphera Inc | 282.9% | Outperformed |
| 4 | Cingulate Inc | 282.9% | Outperformed |
| 5 | Diamedica Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Cosciens Biopharma Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Cosciens Biopharma Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Cosciens Biopharma Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Cosciens Biopharma Inc | 8.61 | 7.50 |
| Ironwood Pharmaceuticals inc | 663.70 | 389.32 |
| Phathom Pharmaceuticals Inc | 611.35 | 239.66 |
| Diamedica Therapeutics Inc | 445.71 | - |
| Relmada Therapeutics Inc | 423.66 | - |
| Nrx Pharmaceuticals Inc | 109.94 | 3.39 |
| SUBTOTAL | 2,523.93 | 709.57 |
Sign in to see all competitors of Cosciens Biopharma Inc .
Sources: Cosciens Biopharma Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Cosciens Biopharma Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Cosciens Biopharma Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Entera Bio | Named by the company | 85% |
| Amolyt Pharma | Named by the company | 85% |
| Extend Biosciences | Named by the company | 85% |
| Ascendis Pharma | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Cosciens Biopharma Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Cosciens Biopharma Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Phathom Pharmaceuticals Inc | Reportable Segment Aggregation Before Other Operating Segment 100.00 % |
| Dar Bioscience Inc | Reportable 100.00 % |
| Integrated Biopharma Inc | Other Nutraceutical Business 2.92 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Cosciens Biopharma Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Cosciens Biopharma Inc | 9 | 267,786 | -369,929 |
| Ironwood Pharmaceuticals inc | 664 | 3,893,160 | 1,298,680 |
| Phathom Pharmaceuticals Inc | 611 | 645,992 | -267,040 |
| Diamedica Therapeutics Inc | 446 | - | -1,072,600 |
| Relmada Therapeutics Inc | 424 | - | -253,834 |
| Nrx Pharmaceuticals Inc | 110 | 117,034 | -774,586 |
| PEERS TOTAL | 2,515 | 780,947 | -120,096 |
Sign in to see all peers for Cosciens Biopharma Inc .
Cosciens Biopharma Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Integrated Biopharma Inc | US 83.83 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Cosciens Biopharma Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 26 companies in Cosciens Biopharma Inc's industry classification, broader than the peer set above. Market cap in millions of $.Cosciens Biopharma Inc ranks #0 of 26 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 2,943, indicating a highly concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Procter and Gamble Co | 358,833 | 50.29 % |
| 2 | Haleon Plc | 84,245 | 11.81 % |
| 3 | Ecolab Inc | 78,174 | 10.96 % |
| 4 | Colgate palmolive Company | 69,424 | 9.73 % |
| 5 | Est e Lauder Companies Inc | 1,234 | 5.2% |
| 6 | Kenvue Inc | 1,234 | 5.2% |
| 7 | Church and Dwight Co Inc | 1,234 | 5.2% |
| 8 | The Clorox Company | 1,234 | 5.2% |
| 9 | E l f Beauty Inc | 1,234 | 5.2% |
| 10 | Yatsen Holding Limited | 1,234 | 5.2% |
| 0 | Cosciens Biopharma Inc | - | 0.00 % |
Market cap and industry share for the rest of Cosciens Biopharma Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-06-08.
Cosciens Biopharma Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Personal & Household Products industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (42 companies). See the full Personal & Household Products industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 35.30 % | 47.63 % (avg) | -12.3 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | 6.35 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 9.42 % | 2.24 % (avg) | +7.2 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Cosciens Biopharma Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | -50.98 % | 34.22 % | -21.79 % |
| Operating Margin | -64.80 % | - | - |
| Return on Invested Capital | - | - | - |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Cosciens Biopharma Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Low | Industry HHI of 2,943 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 9.42 % vs industry average 2.24 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Cosciens Biopharma Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Cosciens Biopharma Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Cosciens Biopharma Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Latest-quarter revenue run-rate is decelerating (-5.8% annualized vs trailing 12 months).
Opportunities
No rule matched.
Threats
- Industry dominated by Procter and Gamble Co, holding 50.29 % of industry market cap.
- Tracked peer group's revenue run-rate is broadly decelerating (-32.5% annualized).
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Cosciens Biopharma Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Cosciens Biopharma Inc | 2.02 | 3.18 | - |
| Ironwood Pharmaceuticals inc | 0.87 | 1.43 | - |
| Phathom Pharmaceuticals Inc | 1.25 | 2.00 | - |
| Diamedica Therapeutics Inc | 2.96 | 9.39 | - |
| Relmada Therapeutics Inc | 0.81 | 17.86 | - |
| Nrx Pharmaceuticals Inc | 0.38 | 0.45 | - |
Sign in to see all peers for Cosciens Biopharma Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Cosciens Biopharma Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Cosciens Biopharma Inc | Q4 2025 | -21.8 % | - |
| Ironwood Pharmaceuticals inc | Q2 2026 | +32.6 % | +117.3 % |
| Phathom Pharmaceuticals Inc | Q2 2026 | +88.0 % | - |
| Diamedica Therapeutics Inc | Q2 2026 | - | - |
| Relmada Therapeutics Inc | Q2 2026 | - | - |
| Nrx Pharmaceuticals Inc | Q2 2026 | - | - |
| PEERS TOTAL | +25.6 % | - |
Sign in to see all peers for Cosciens Biopharma Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Cosciens Biopharma Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Cosciens Biopharma Inc | Q4 2025 | -0.1 % | -39.2 % |
| Ironwood Pharmaceuticals inc | Q2 2026 | - | - |
| Phathom Pharmaceuticals Inc | Q2 2026 | +199.6 % | -54.6 % |
| Diamedica Therapeutics Inc | Q2 2026 | - | -50.0 % |
| Relmada Therapeutics Inc | Q2 2026 | - | - |
| Nrx Pharmaceuticals Inc | Q2 2026 | - | - |
Sign in to see all peers for Cosciens Biopharma Inc .
Cosciens Biopharma Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Cosciens Biopharma Inc | - | - | - |
| Ironwood Pharmaceuticals inc | 34.34% | 70.54% | - |
| Phathom Pharmaceuticals Inc | - | - | - |
| Diamedica Therapeutics Inc | - | - | - |
| Relmada Therapeutics Inc | - | - | - |
| Nrx Pharmaceuticals Inc | - | - | - |
Sign in to see all peers for Cosciens Biopharma Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Cosciens Biopharma Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Cosciens Biopharma Inc | - | 1.15 |
| Ironwood Pharmaceuticals inc | 5.16 | 1.70 |
| Phathom Pharmaceuticals Inc | 4.17 | 2.55 |
| Diamedica Therapeutics Inc | - | - |
| Relmada Therapeutics Inc | 11.78 | - |
| Nrx Pharmaceuticals Inc | - | 32.39 |
| PEERS AVERAGE | - | 3.56 |
Sign in to see all peers for Cosciens Biopharma Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.